Last reviewed · How we verify
Zinc and Copper
Zinc and Copper is a Mineral supplement / Trace element replacement Small molecule drug developed by Phoenix Neurological Associates, LTD. It is currently FDA-approved for Zinc and copper deficiency in neurological conditions, Supportive therapy in neurodegenerative or neurological disorders.
Zinc and copper act as essential cofactors for metalloenzymes and antioxidant systems, supporting neurological function and reducing oxidative stress.
Zinc and Copper are small molecule micronutrients that have been studied in various clinical trials for conditions such as multiple micronutrient deficiencies during pregnancy, premature ovarian failure, iron-deficiency, men infertility, and colorectal cancer. They are often supplemented in the form of multiple micronutrient supplements or iron and folic acid (IFA) to address these conditions.
At a glance
| Generic name | Zinc and Copper |
|---|---|
| Sponsor | Phoenix Neurological Associates, LTD |
| Drug class | Mineral supplement / Trace element replacement |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zinc and copper are trace minerals that serve as cofactors for numerous enzymes involved in neurological health, including superoxide dismutase (SOD) and cytochrome c oxidase. They support synaptic plasticity, myelin formation, and antioxidant defense mechanisms. This combination is used to address mineral deficiencies that may contribute to neurological dysfunction.
Approved indications
- Zinc and copper deficiency in neurological conditions
- Supportive therapy in neurodegenerative or neurological disorders
Common side effects
- Gastrointestinal upset
- Nausea
- Copper toxicity (with excessive supplementation)
- Zinc-induced copper malabsorption
Key clinical trials
- A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease (PHASE1, PHASE2)
- Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
- FIBERGRAFT Aeridyan Posterolateral Fusion Study (NA)
- Effectiveness of Pulsed Electromagnetic Fields and Nutraceutical Supplementation in Women With Distal Radius Fracture (NA)
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
- Chemo Brain Prehab Project (NA)
- Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue (PHASE3)
- Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zinc and Copper CI brief — competitive landscape report
- Zinc and Copper updates RSS · CI watch RSS
- Phoenix Neurological Associates, LTD portfolio CI
Frequently asked questions about Zinc and Copper
What is Zinc and Copper?
How does Zinc and Copper work?
What is Zinc and Copper used for?
Who makes Zinc and Copper?
What drug class is Zinc and Copper in?
What development phase is Zinc and Copper in?
What are the side effects of Zinc and Copper?
Related
- Drug class: All Mineral supplement / Trace element replacement drugs
- Manufacturer: Phoenix Neurological Associates, LTD — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Zinc and copper deficiency in neurological conditions
- Indication: Drugs for Supportive therapy in neurodegenerative or neurological disorders
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing